Loading...
2 results
Search Results
Now showing 1 - 2 of 2
- Recent therapeutic applications of the theranostic principle with dendrimers in oncologyPublication . Mignani, Serge; Rodrigues, João; Tomás, Helena; Caminade, Anne-marie; Laurent, Régis; Shi, Xiangyang; Majoral, Jean-PierreAt the intersection between treatment and diagnosis,nanoparticlestechnologiesarestronglyimpactingthe development of both therapeutic and diagnostic agents. Consequently, the development of novel modalities for concomitant noninvasive therapy and diagnostics known as theranostics as a single platform has gained significant interests. These multifunctional theranostic platforms include carbon-based nanomaterials (e.g., carbon nanotubes), drug conjugates, aliphatic polymers, micelles, vesicles, core-shell nanoparticles,microbubblesanddendrimersbearingdifferent contrastagentsanddrugs,suchascytotoxiccompoundsinthe oncology domain. Dendrimers emerged as a new class of highly tunable hyperbranched polymers, and have been developed as useful theranostic platforms. Magnetic resonance imaging, gamma scintigraphy, computed tomography and optical imaging are the main techniques developed with dendrimers in the theranostic domain in oncology. Different imaging agents have been used such as Gd(III), 19F, Fe2O3 (MRI), 76Br (PET), 111In, 88Y, 153Gd, 188Re, 131I (SPECT), 177Lu, gold (CT) and boronated groups, siliconnaphthalocyanines, dialkylcarbocyanines and QDs (optical imaging dyes).
- Dendrimers in combination with natural products and analogues as anti-cancer agentsPublication . Mignani, Serge; Rodrigues, João; Tomás, Helena; Zablocka, Maria; Shi, Xiangyang; Caminade, Anne-marie; Majoral, Jean-PierreFor the first time, an overview of dendrimers in combination with natural products and analogues as anti-cancer agents is presented. This reflects the development of drug delivery systems, such as dendrimers, to tackle cancers. The most significant advantages of using dendrimers in nanomedicine are their high biocompatibility, good water solubility, and their entry - with or without encapsulated, complexed or conjugated drugs - through an endocytosis process. This strategy has accelerated over the years in order to develop nanosystems as nanocarriers, to decrease the intrinsic toxicity of anti-cancer agents, to decrease the drug side effects, to increase the efficacy of the treatment, and consequently to improve patient compliance.